Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered Immune Effector Cells (EIE) in Gastro-Intestinal Cancer
NCT03614650Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Jun 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Engineered Immune Effector therapy in gastrointestinal cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
Engineered Immune Effector therapy
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT03614650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614650.